Europe
Roche announced interim results from its Phase III IMvigor130 clinical trial, indicating it met its co-primary endpoint of progression-free survival. The trial evaluated the combination of Tecentriq and platinum-based chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma compared to chemotherapy alone.
Pratteln, Switzerland, August 2, 2019 – Santhera Pharmaceuticals announces the closing of the licensing transaction with Chiesi Farmaceutici, an international research-focused healthcare group.
Revelations could personalise treatment, including picking out those likely to benefit from immunotherapy
Every week brings news of clinical trials, ranging from launches, first-patient dosing, full enrollment, interim data or final data. Here’s a look at some of the clinical trial news from last week.
Almac Pharma Services, part of the global contract pharmaceutical development and manufacturing organisation, the Almac Group, is inviting members of the pharmaceutical and biotechnology industry to join its upcoming complimentary workshop series this September.
Evotec SE and Lygature announced their cooperation in a new initiative for the development of novel antibacterial agents.
Supporting rare disease diagnosis, education, and clinical research
Clinically advanced vaccine, ACI-35.030, designed to reduce and to prevent the spread and development of Tau pathology
Cristal Therapeutics announces that Dr Werner Cautreels is joining the Company’s supervisory board taking on the role of Chairman.
The Journal of Medical Device Regulation’s recently redesigned website – www.GlobalRegulatoryPress.com – reflects the Journal’s emphasis on complete customer satisfaction.
PRESS RELEASES